CAR T-Cell Therapy in Autoimmune Disease

Dr. Howard, Jr., reports receiving research support (paid to his institution) from Alexion AstraZeneca Rare Disease, Argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention, the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (NIH, including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), the Patient-Centered Outcomes Research Institute, Ra Pharmaceuticals (now UCB), and Takeda Pharmaceuticals, honoraria from Alexion AstraZeneca Rare Disease, Argenx, Biologix, Immunovant, Merck EMD Serono, NMD Pharma, Novartis, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi US, Viela Bio/Horizon Therapeutics (now Amgen), and Zai Lab, and coverage of travel expenses to attend advisory board meetings from Alexion Pharmaceuticals, Argenx, Ra Pharmaceuticals (now UCB), Toleranzia, and Zai Lab. Dr. Vu reports being the University of South Florida site principal investigator for myasthenia gravis clinical trials sponsored by Alexion/AstraZeneca, Argenx, Cartesian Therapeutics, Dianthus Therapeutics, Horizon Therapeutics/Viela Bio, Immunovant, Janssen/Momenta Pharmaceuticals, Ra Pharmaceuticals/UCB, and Regeneron Pharmaceuticals and receiving speaking or consulting honoraria relating to myasthenia gravis from Alexion Pharmaceuticals, Argenx, and UCB. Dr. Mozaffar reports receiving research support (paid to his institution) from Alexion Pharmaceuticals, Amicus, Annji, Argenx, Astellas Gene Therapy, Cartesian Therapeutics, ML Bio, Sanofi, Spark Therapeutics, UCB, and Valerion, receiving consulting fees from Alexion Pharmaceuticals, Amicus Therapeutics, AnnJi Pharmaceutical, Argenx, Audentes/Astellas Gene Therapies, Horizon Therapeutics, Maze Therapeutics, Momenta Pharmaceuticals, Sanofi, and UCB, receiving support for meetings or travel from Sanofi, and participating on a data and safety monitoring board or an advisory board for Applied Therapeutics, the NIH, and Sarepta Therapeutics. No other potential conflict of interest relevant to this letter was reported.